We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Systolic Hypertension Global Clinical Trials Review, H2, 2018

Published: August 2018
Pages: 83
Code: 5FFCF17FA2ABC665634C78C75CDA74CB
Format: PDF
Publisher GlobalData
From Add to basket
$ 2,500.00
GlobalData's clinical trial report, “ provides an overview of Systolic Hypertension clinical trials scenario. This report provides top line data relating to the clinical trials on Systolic Hypertension. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData’s proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.
The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.
*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Additonal Information

  • - The report provides a snapshot of the global clinical trials landscape
  • - Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
  • - The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
  • - The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
  • - The Report provides enrollment trends for the past five years
  • - Report provides latest news for the past three months
  • *Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Companies Mentioned

Novartis AG
Merck & Co Inc
C. H. Boehringer Sohn AG & Co KG
Bristol-Myers Squibb Co
Gilead Sciences Inc
Synvista Therapeutics Inc
Sanofi
Metabolic Research Institute Inc
Daiichi Sankyo Co Ltd
A. Menarini Industrie Farmaceutiche Riunite Srl

Reasons to buy

Assists in formulating key business strategies with regards to investment Helps in identifying prominent locations for conducting clinical trials which saves time and cost Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities Supports understanding of trials count and enrollment trends by country in global therapeutics market Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials Facilitates clinical trial assessment of the indication on a global, regional and country level *Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Add to basket
  • Table of Contents
  • Table of Contents 2
  • List of Tables 3
  • List of Figures 4
  • Report Guidance 5
  • GlobalData Clinical Trials Report Coverage 6
  • Clinical Trials by Region 7
  • Clinical Trials and Average Enrollment by Country 8
  • Top Five Countries Contributing to Clinical Trials in Asia-Pacific 11
  • Top Five Countries Contributing to Clinical Trials in Europe 12
  • Top Countries Contributing to Clinical Trials in North America 13
  • Top Countries Contributing to Clinical Trials in Middle East and Africa 14
  • Top Countries Contributing to Clinical Trials in Central and South America 15
  • Clinical Trials by G7 Countries: Proportion of Systolic Hypertension to Cardiovascular Clinical Trials 16
  • Clinical Trials by Phase in G7 Countries 18
  • Clinical Trials in G7 Countries by Trial Status 19
  • Clinical Trials by E7 Countries: Proportion of Systolic Hypertension to Cardiovascular Clinical Trials 20
  • Clinical Trials by Phase in E7 Countries 22
  • Clinical Trials in E7 Countries by Trial Status 23
  • Clinical Trials by Phase 24
  • In Progress Trials by Phase 25
  • Clinical Trials by Trial Status 26
  • Clinical Trials by End Point Status 28
  • Subjects Recruited Over a Period of Time 29
  • Clinical Trials by Sponsor Type 30
  • Prominent Sponsors 31
  • Top Companies Participating in Systolic Hypertension Therapeutics Clinical Trials 33
  • Prominent Drugs 35
  • Clinical Trial Profile Snapshots 36
  • Appendix 81
  • Abbreviations 81
  • Definitions 81
  • Research Methodology 82
  • Secondary Research 82
  • About GlobalData 82
  • Contact Us 83
  • Disclaimer 83
  • Source 83
  • List of Tables
  • Systolic Hypertension Therapeutics, Global, Clinical Trials by Region, 2018* 7
  • Systolic Hypertension Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2018* 9
  • Systolic Hypertension Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2018* 10
  • Systolic Hypertension Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2018* 11
  • Systolic Hypertension Therapeutics Clinical Trials, Europe, Top Five Countries, 2018* 12
  • Systolic Hypertension Therapeutics Clinical Trials, North America, Top Countries, 2018* 13
  • Systolic Hypertension Therapeutics Clinical Trials, Middle East and Africa, Top Countries, 2018* 14
  • Systolic Hypertension Therapeutics Clinical Trials, Central and South America, Top Countries, 2018* 15
  • Proportion of Systolic Hypertension to Cardiovascular Clinical Trials, G7 Countries (%), 2018* 17
  • Systolic Hypertension Therapeutics, G7 Countries, Clinical Trials by Phase, 2018* 18
  • Systolic Hypertension Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2018* 19
  • Proportion of Systolic Hypertension to Cardiovascular Clinical Trials, E7 Countries (%), 2018* 21
  • Systolic Hypertension Therapeutics, E7 Countries, Clinical Trials by Phase, 2018* 22
  • Systolic Hypertension Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2018* 23
  • Systolic Hypertension Therapeutics, Global, Clinical Trials by Phase, 2018* 24
  • Systolic Hypertension Therapeutics, Global, Clinical Trials In Progress by Phase 2018* 25
  • Systolic Hypertension Therapeutics, Global, Clinical Trials by Trial Status, 2018* 27
  • Systolic Hypertension Therapeutics Clinical Trials, Global, by End Point Status, 2018* 28
  • Systolic Hypertension Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2013-2017 29
  • Systolic Hypertension Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2018* 30
  • Systolic Hypertension Therapeutics Clinical Trials, Global, Key Sponsors, 2018* 32
  • Systolic Hypertension Therapeutics Clinical Trials, Global, Top Companies by Phase, 2018* 34
  • Systolic Hypertension Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2018* 35
  • List of Figures
  • Systolic Hypertension Therapeutics, Global, Clinical Trials by Region (%), 2018* 7
  • Systolic Hypertension Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2018* 8
  • Systolic Hypertension Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2018* 10
  • Systolic Hypertension Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2018* 11
  • Systolic Hypertension Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2018* 12
  • Systolic Hypertension Therapeutics Clinical Trials, North America, Top Countries (%), 2018* 13
  • Systolic Hypertension Therapeutics Clinical Trials, Middle East and Africa, Top Countries (%), 2018* 14
  • Systolic Hypertension Therapeutics Clinical Trials, Central and South America, Top Countries (%), 2018* 15
  • Proportion of Systolic Hypertension to Cardiovascular Clinical Trials, G7 Countries (%), 2018* 16
  • Systolic Hypertension Therapeutics, G7 Countries, Clinical Trials by Phase, 2018* 18
  • Systolic Hypertension Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2018* 19
  • Proportion of Systolic Hypertension to Cardiovascular Clinical Trials, E7 Countries (%), 2018* 20
  • Systolic Hypertension Therapeutics, E7 Countries, Clinical Trials by Phase, 2018* 22
  • Systolic Hypertension Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2018* 23
  • Systolic Hypertension Therapeutics, Global, Clinical Trials by Phase (%), 2018* 24
  • Systolic Hypertension Therapeutics, Global, Clinical Trials In Progress by Phase, 2018* 25
  • Systolic Hypertension Therapeutics, Global, Clinical Trials by Trial Status, 2018* 26
  • Systolic Hypertension Therapeutics Clinical Trials, Global, by End Point Status, 2018* 28
  • Systolic Hypertension Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2013-2017 29
  • Systolic Hypertension Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2018* 30
  • Systolic Hypertension Therapeutics Clinical Trials, Global, Key Sponsors, 2018* 31
  • Systolic Hypertension Therapeutics Clinical Trials, Global, Top Companies by Phase, 2018* 33
  • Systolic Hypertension Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2018* 35
  • GlobalData Methodology 82

Keywords
;